Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Udenafil (WC3055) in Men with LUTS Secondary to BPH
NCT01939184Phase 2Completed
- Sponsor
- Warner Chilcott
- Start
- Aug 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of udenafil in benign prostatic hyperplasia (BPH) (5 arms), sponsored by Warner Chilcott. Primary endpoint: International Prostate Symptom Score at 12 weeks. Started Aug 2013; status: completed.
02
Drugs
udenafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01939184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939184.